Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques
- Abbreviated Name
- Lung CARET
- Lead Investigator
- Hanash, Samir — The University of Texas MD Anderson Cancer Center
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
Abstract
see objectives
Aims
Aim 1: To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis. Aim 2: To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type. Aim 3: To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Analytic Method
Natural Array technique
Outcome
see objectives
Publications
- Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.
Biomarkers
- 14-3-3 theta
- Annexin 1 and SOX2
- ANXA1
- APEX1
- CYGB
- DAPK1
- EFEMP1
- Halling 4 marker LAVysion lung cancer probe set
- Hanash 3 marker panel for Lung Cancer
- LAMR1
- MPG
- OGG1
- PARK7
- PGP
- TCF21
- UCHL1
Data Collections
- Start Date
- Sep 5 2006
- Estimated Finish Date
- Sep 5 2007
- Finish Date
- Aug 7 2007
- Protocol ID
- 138
- Protocol Type
- Validation
- Fields of Research
-
- Proteomics
- Collaborative Group
- Lung and Upper Aerodigestive Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bronchus and lung
- Phased Status
- 2